Key points
- FY26 marked transition to early cancer detection platform
- Expanded portfolio to include pancreatic and ovarian tests
- Secured funding for FY27 activities
- Appointed new CEO and Non-Executive Director
- Acquired strategic stake in Genetic Signatures Ltd
Full summary
BCAL Diagnostics Ltd's FY26 Annual Report highlights significant advancements in its early cancer detection platform. The company expanded its portfolio with the addition of pancreatic and ovarian tests, launched through partnerships with ClearNote Health and pathology networks. BCAL secured funding to support its FY27 activities, including further development and commercialization of its tests. Leadership changes included the appointment of Anne-Louise Arnett as CEO and Mark McConnell as Non-Executive Director. Additionally, BCAL acquired a strategic stake in Genetic Signatures Ltd, enhancing its market position and access to complementary diagnostics infrastructure.
Guidance
BCAL Diagnostics Ltd expects to progress commercialization in FY27 with increased test adoption.
Outlook
BCAL Diagnostics Ltd is focused on increasing commercial adoption of its test portfolio in FY27, while continuing validation, evidence generation, and market access efforts.